Dimeric GYS1 Inhibitor Compounds for Metabolic Disorder Treatment
Summary
USPTO published patent application US20260098025A1 covering dimeric compounds of formula (I) as inhibitors of glycogen synthase 1 (GYS1), along with methods of preparing the compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. The application names nine inventors including David John Morgans Jr. and Christopher Joseph Sinz, with an original filing date of September 13, 2023.
What changed
USPTO published patent application US20260098025A1 disclosing dimeric compounds of formula (I) — structured as (G1-Z1)-L-(G2-Z2) — and their use as inhibitors of glycogen synthase 1 (GYS1), an enzyme implicated in glycogen metabolism. The application covers methods of preparing these compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. Nine inventors are listed including David John Morgans Jr., Christopher Joseph Sinz, and Nathan Fastman. The application was originally filed September 13, 2023.
Pharmaceutical companies and biotechnology firms developing therapies for metabolic disorders such as diabetes, obesity, and fatty liver disease should review the pending claims for potential overlap with their own research programs. Investors tracking metabolic disorder therapeutics should monitor the prosecution of this application for future market exclusivity implications.
What to do next
- Review pending claims for freedom-to-operate implications
- Monitor for USPTO examination and potential grant
- Assess therapeutic overlap with existing metabolic disorder pipelines
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF
Application US20260098025A1 Kind: A1 Apr 09, 2026
Inventors
David John MORGANS, JR., Kevin MELLEM, Patrick Sang Tae LEE, Christopher Joseph SINZ, Alexander Wayne SCHAMMEL, Chris ZIEBENHAUS, Jessica WAHLERS, Christos TZITZILONIS, Nathan FASTMAN
Abstract
Provided herein are compounds of formula (I): (G1-Z1)-L-(G2-Z2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G1, G2, Z1, Z2, and L, are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.
CPC Classifications
C07D 401/14 A61K 31/444 A61K 31/513 A61K 38/47 A61K 47/55 C07D 213/61 C12Y 302/0102
Filing Date
2023-09-13
Application No.
19111739
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.